Chinese Trial Data Won’t Cut It for Lung Cancer Drug, FDA Panel Says

Sintilimab “potentially has application, but it hasn’t been proven. So it is problematic from that standpoint,” said Christopher Lieu, of University of Colorado, who voted to wait on further data. Though he noted that given the drug’s mechanism of action, “it’s going to be hard to believe that the data is going to be extraordinarily different in the U.S. population.”